TY  - JOUR
AU  - Hotta, Masatoshi
AU  - Gafita, Andrei
AU  - Murthy, Vishnu
AU  - Benz, Matthias R
AU  - Sonni, Ida
AU  - Burger, Irene A
AU  - Eiber, Matthias
AU  - Emmett, Louise
AU  - Farolfi, Andrea
AU  - Fendler, Wolfgang P
AU  - Weber, Manuel M
AU  - Hofman, Michael S
AU  - Hope, Thomas A
AU  - Kratochwil, Clemens
AU  - Czernin, Johannes
AU  - Calais, Jeremie
TI  - PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.
JO  - Journal of nuclear medicine
VL  - 64
IS  - 7
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2023-00659
SP  - 1024-1029
PY  - 2023
N1  - 2023 Jul;64(7):1024-1029
AB  - Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy can improve the outcome of patients with advanced metastatic castration-resistant prostate cancer, but patients do not respond uniformly. We hypothesized that using the salivary glands as a reference organ can enable selective patient stratification. We aimed to establish a PSMA PET tumor-to-salivary gland ratio (PSG score) to predict outcomes after [177Lu]PSMA. Methods: In total, 237 men with metastatic castration-resistant prostate cancer treated with [177Lu]PSMA were included. A quantitative PSG (qPSG) score (SUVmean ratio of whole-body tumor to parotid glands) was semiautomatically calculated on baseline [68Ga]PSMA-11 PET images. Patients were divided into 3 groups: high (qPSG > 1.5), intermediate (qPSG = 0.5-1.5), and low (qPSG < 0.5) scores. Ten readers interpreted the 3-dimensional maximum-intensity-projection baseline [68Ga]PSMA- 11 PET images and classified patients into 3 groups based on visual PSG (vPSG) score: high (most of the lesions showed higher uptake than the parotid glands) intermediate (neither low nor high), and low (most of the lesions showed lower uptake than the parotid glands). Outcome data included a more than 50
KW  - Oncology: GU (Other)
KW  - PET (Other)
KW  - PET/CT (Other)
KW  - PSMA PET (Other)
KW  - Radionuclide Therapy (Other)
KW  - [177Lu]PSMA (Other)
KW  - parotid glands (Other)
KW  - radioligand therapy (Other)
KW  - visual criteria (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36997329
DO  - DOI:10.2967/jnumed.122.265242
UR  - https://inrepo02.dkfz.de/record/274582
ER  -